China NMPA Drug Inspection - Guangxi Nanning Dezhi Pharmaceutical Co., Ltd. - Shuanghuang Anti-inflammatory Tablets
China NMPA drug inspection for Guangxi Nanning Dezhi Pharmaceutical Co., Ltd. published August 29, 2019. Drug: Shuanghuang Anti-inflammatory Tablets. The National Medical Products Administration (NMPA) of China issued Announcement No. 60 of 2019 on August 27, 2019, publ
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Guangxi Nanning Dezhi Pharmaceutical Co., Ltd. published August 29, 2019. Drug: Shuanghuang Anti-inflammatory Tablets. The National Medical Products Administration (NMPA) of China issued Announcement No. 60 of 2019 on August 27, 2019, publ
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox